>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
不可手术的原发性肝癌放疗效果影响因素及预后分析
作者:田小强1  鲁世慧2  王礼学2  杜傲宇2  郑勤1  童金龙1 2 
单位:中医药大学附属南京医院(南京市第二医院)
1. 肿瘤科,
2. 放疗科, 江苏 南京 210003
关键词:放疗 肝癌 疗效 预后 影响因素 
分类号:R459.9
出版年·卷·期(页码):2019·38·第六期(1029-1034)
摘要:

目的:探讨三维适形/适形调强放疗对不可手术的原发性肝癌的治疗效果、不良反应以及影响疗效和预后的相关因素。方法:回顾性分析2013年7月至2016年5月我院45例行放疗的不可手术的原发性肝癌患者(其中12例合并静脉癌栓,33例曾行肝动脉化疗栓塞术)的临床资料。患者放疗结束后1~3个月观察近期疗效,随访1、2、3年,对影响疗效和预后的相关因素进行分析。结果:放疗后肝癌原发灶完全缓解(CR)4例(8.9%),部分缓解(PR)16例(35.5%),疾病稳定(SD)17例(37.8%),疾病进展(PD)8例(17.8%);静脉癌栓者CR 1例(8.33%),PR 3例(25.0%),SD 6例(50.0%)和PD 2例(16.67%)。肝癌原发灶及静脉癌栓放疗客观缓解率分别为44.4%和33.3%。放疗期间出现Ⅲ度以上的不良反应有恶心呕吐、骨髓抑制、食欲下降和疲乏等。影响放疗效果的因素有肿瘤直径、ΔCT值、肿瘤处方剂量以及是否曾接受介入治疗。45例患者1、2、3年生存率分别为59.8%、40.9%和2.22%。多因素分析结果显示,肿瘤体积、肿瘤分期、静脉癌栓是影响预后的重要因素。结论:三维适形/适形调强放疗对不可手术原发性肝癌疗效较好,不良反应患者可耐受。肿瘤的直径、血供、肿瘤处方剂量是影响肝癌放疗效果的关键因素,肿瘤体积、分期及是否合并静脉癌栓是影响预后的独立因素。

Objective: To investigate the efficacy, adverse reactions and influence factors of three-dimensional conformal/intensity modulated radiotherapy(3D-CRT/IMRT) for inoperable primary hepatocellular carcinoma(HCC). Methods: The clinic data of 45 patients with inoperable primary HCC who received 3D-CRT/IMRT in our hospital from July 2013 to May 2016 were retrospectively studied, including 12 patients with portal vein tumor thrombus, and 33 patients underwent transarterial chemoembolization (TACE) before radiotherapy. The short-term efficacy of the treatment was observed 1-3 months after radiotherapy. These patients were followed up for 1,2, and 3 years and the factors of influencing efficacy and prognosis were analyzed. Results: After radiotherapy, there were 4 cases (8.9%) complete remission(CR), 16 cases (35.5%) partial remission(PR), 17 cases (37.8%) stable disease (SD), and 8 cases progressive disease (PD) (17.8%) in primary liver leision. In the patients with venous thrombus, 1 case was CR(8.33%),3 cases were PR(25.0%),6 cases were SD(50.0%)and 2 cases were PD(16.67%). Objective remission rates of primary liver leision and venous thrombus after radiotherapy were 44.4%and 33.3%, respectively. During the radiotherapy, the adverse reactions more than Ⅲ degree were nausea and vomiting, myelosuppression, loss of appetite and fatigue. Factors influencing the efficacy of radiotherapy included tumor diameter, ΔCT value, prescription dose and ever received interventional therapy. The 1-year, 2-year and 3-year survival rates of the patients underwent 3D-CRT/IMRT were 59.8%, 40.9%and 2.22%, respectively. Multivariate analysis showed that tumor volume, tumor stage and tumor venous thrombus were the important factors affecting prognosis. Conclusion: 3D-CRT/IMRT is an effective method in the treatment of inoperable primary HCC with low adverse reactions and good tolerance. Tumor diameter, blood supply and radiotherapy dose are the key factors affecting the efficacy of radiotherapy on liver cancer, and tumor volume, stage and tumor thrombus are independent factors affecting the prognosis of patients.

参考文献:

[1] CHINO F,STEPHENS S J,CHOI S S,et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer[J].Cancer,2018,124(17):3476-3489.
[2] ZENG Z C,JIANG G L,WANG G M,et al. DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line[J]. World J Gastroenterol,2002,8(5):797-803.
[3] 中华人民共和国卫生部,原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946.
[4] Korean Liver Cancer Study Group (KLCSG),National Cancer Center.Korea (NCC).2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma[J]. Korean J Radiol,2015,16(3):465-522.
[5] 中华医学会放射肿瘤学分会,中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会,中国研究型医院学会放射肿瘤学分会肝癌学组.2016年原发性肝癌放疗共识[J].中华放射肿瘤学杂志,2016,25(11):1141-1150.
[6] 童金龙,郑勤,孙新臣.原发性肝癌SBRT研究进展[J].中华放射肿瘤学杂志,2017,26(2):234-38.
[7] 孙庆春.肝癌中晚期给予恩度肝动脉灌注治疗辅以介入化疗栓塞术的临床研究[J].中国社区医师,2016,32(25):43-44.
[8] CHA H,PARK H C,YU J I,et al. Clinical practice patterns of radiotherapy in patients with hepatocellular carcinoma:A Korean Radiation Oncology Group Study (KROG 14-07)[J]. Cancer Res Treat,2017,49(1):61-69.
[9] YOON S M,LIM Y S,et al.Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein:long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys,2012,82(5):2004-2011.
[10] HUO Y R,ESLICK G D. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:A systematic review and meta-analysis[J]. JAMA Oncol. 2015,1(6):756-765.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 243148 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364